Published in

Lippincott, Williams & Wilkins, Journal of Acquired Immune Deficiency Syndromes, 2(62), p. 204-207, 2013

DOI: 10.1097/qai.0b013e31827ce536

Links

Tools

Export citation

Search in Google Scholar

Impact of Hepatitis C Virus on HIV Response to Antiretroviral Therapy in Nigeria

Journal article published in 2013 by Oche Agbaji, Chloe L. Thio, Seema Meloni, Camilla Graham, Mohammed Muazu, Ladep Nimzing, John Idoko, Jean-Louis Sankalé, Ernest Ekong, Robert Murphy ORCID, Phyllis Kanki, Claudia Hawkins
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The effect of HCV on ART response in patients in sub-Saharan Africa is unknown. We studied 1431 HIV-infected ART initiators in Jos, Nigeria of whom 6% were HCV co-infected. A similar proportion of HIV-HCV co-infected and HIV-mono-infected patients achieved HIV RNA 0.05). Hepatotoxicity was uncommon (0.8% and 0.33% at 24 and 48 weeks, respectively), but was more common in the HIV-HCV co-infected group at 24 (aOR=19.3; 95% CI: 4.41–84.4) and 48 weeks (aOR=56.7; 95% CI: 5.03–636.92). HCV did not significantly impact ART response in this Nigerian cohort.